SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Divis Laboratories

Divis Laboratories

BSE: 532488|NSE: DIVISLAB|ISIN: INE361B01024|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Jul 01, 15:40
1138.00
26.55 (2.39%)
VOLUME 84,389
LIVE
NSE
Jul 01, 15:40
1133.60
23.95 (2.16%)
VOLUME 441,148
News on Divis Laboratories
Select Year: 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Bull's Eye: Buy Idea, Mindtree, Ceat, Praj Ind; sell Biocon 

7.55 am | 29 Jun 2016 |  Source: CNBC-TV18

Sameet Chavan of Angel Broking is of the view that one may buy Ceat with a target of Rs 840....

Bull's Eye: Buy Bajaj Auto, Exide, DLF; sell Apollo Tyres 

7.58 am | 28 Jun 2016 |  Source: CNBC-TV18

Sameet Chavan of Angel Broking advises buying Bajaj Auto with a target of Rs 2850....

'If you want to make outsized returns, buy during uncertainty' 

11.30 am | 17 Jun 2016 |  Source: CNBC-TV18

Madhu Kela of Reliance Capital, who called the bottom of the market around its 6,800 lows in February, added that near-term returns, especially in sto...

Divis Lab, Glenmark look weak; buy Bharti Airtel: Rajat Bose 

9.57 am | 07 Jun 2016 |  Source: CNBC-TV18

According to Rajat Bose of rajatkbose.com, Divis Laboratories and Glenmark Pharma are looking pretty weak....

Bull's Eye: Buy Tata Global, UPL, Wockhardt, Voltas, Divis Lab 

7.58 am | 03 Jun 2016 |  Source: CNBC-TV18

Manish Sharma of derivativetradingresearch.com is of the view that one may buy Tata Global with a target of Rs 128....

Buy Divis Laboratories; target of Rs 1260: Religare

4.47 pm | 30 May 2016 |  Source: Moneycontrol.com

Religare is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 1260 in its research report dated May 29, ...

Here are a few stocks to keep an eye on May 30 

9.02 am | 30 May 2016 |  Source: CNBC-TV18

Here are a few stocks to focus on May 30- HCL Technologies, Indiabulls Housing Finance, SBI, Coal India, Crompton Greaves, Reliance Infra, Kalpataru P...

Divis Labs Q4 net seen up 10%, generic biz may support topline

5.39 pm | 27 May 2016 |  Source: CNBC-TV18

Topline growth may be on the back of increased capacity utilisation at new SEZ units and generic business. Analysts feel capacity utilisation rates sh...

Buy Divis Labs; target of Rs 1260: Religare

1.31 pm | 28 Mar 2016 |  Source: Moneycontrol.com

Religare is bullish on Divis Labs has recommended buy rating on the stock with a target price of Rs 1260 in its research report dated March 15, 2016...

Motilal Oswal: neutral on Divis Labs; target of Rs 1180

2.09 pm | 10 Feb 2016 |  Source: Moneycontrol.com

Motilal Oswal has recommended neutral rating on Divis Labs with a target price of Rs 1180 in its research report dated February 8, 2016....

Buy Divis Labs; target of Rs 1305: Religare

5.31 pm | 09 Feb 2016 |  Source: Moneycontrol.com

Religare is bullish on Divis Labs Ind has recommended buy rating on the stock with a target price of Rs 1305 in its research report dated February 8, ...

Divis Labs Q3 misses estimates, profit rises 12% to Rs 247 cr

4.10 pm | 05 Feb 2016 |  Source: Moneycontrol.com

Operating profit (earnings before interest, tax, depreciation and amortisation) grew by 12.3 percent to Rs 322.3 crore and margin expanded by 150 basi...

Divis Labs Q3 profit seen up 26% on strong EBITDA, revenue

9.44 am | 05 Feb 2016 |  Source: CNBC-TV18

Operating profit in Q3 is likely to jump 28.2 percent to Rs 364 crore and margin may expand 240 basis points to 38.4 percent compared to year-ago peri...

1 2 3
Quick Links for Divis Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.